{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:08:25Z","timestamp":1786993705467,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA180794"],"award-info":[{"award-number":["CA180794"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180821"],"award-info":[{"award-number":["U10CA180821"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180888"],"award-info":[{"award-number":["U10CA180888"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189859"],"award-info":[{"award-number":["UG1CA189859"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA232760"],"award-info":[{"award-number":["UG1CA232760"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA233196"],"award-info":[{"award-number":["UG1CA233196"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA233234"],"award-info":[{"award-number":["UG1CA233234"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA23329"],"award-info":[{"award-number":["UG1CA23329"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA233327"],"award-info":[{"award-number":["UG1CA233327"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA233328"],"award-info":[{"award-number":["UG1CA233328"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA180820"],"award-info":[{"award-number":["CA180820"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA189847"],"award-info":[{"award-number":["UG1CA189847"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.leukres.2021.106736","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T19:53:49Z","timestamp":1635450829000},"page":"106736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3364-4366","authenticated-orcid":false,"given":"Selina M.","family":"Luger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Paietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold B.","family":"Rybka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda W.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel Z.","family":"Makary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne S.","family":"Kaminer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2021.106736_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-4-56","article-title":"Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia","volume":"4","author":"Raponi","year":"2004","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.leukres.2021.106736_bib0010","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","article-title":"Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial","volume":"97","author":"Karp","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2021.106736_bib0015","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/leu.2011.124","article-title":"A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia","volume":"25","author":"Kirschbaum","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2021.106736_bib0020","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1182\/blood-2006-09-046144","article-title":"A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia","volume":"109","author":"Harousseau","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2021.106736_bib0025","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2006-04-014357","article-title":"A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia","volume":"109","author":"Lancet","year":"2007","journal-title":"Blood"},{"issue":"May (10)","key":"10.1016\/j.leukres.2021.106736_bib0030","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/1078-0432.CCR-07-4743","article-title":"Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features","volume":"14","author":"Karp","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"282","key":"10.1016\/j.leukres.2021.106736_bib0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.leukres.2021.106736_bib0040","series-title":"A Report on the Natural Duration of Cancer","author":"Greenwood","year":"1926"},{"issue":"3","key":"10.1016\/j.leukres.2021.106736_bib0045","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother. Rep."},{"issue":"2","key":"10.1016\/j.leukres.2021.106736_bib0050","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B"},{"issue":"2","key":"10.1016\/j.leukres.2021.106736_bib0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF01698132","article-title":"Maintenance with low-dose cytarabine for acute myeloid leukemia in complete remission","volume":"65","author":"Archimbaud","year":"1992","journal-title":"Ann. Hematol."},{"issue":"30","key":"10.1016\/j.leukres.2021.106736_bib0060","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1200\/JCO.2008.17.0472","article-title":"Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720","volume":"26","author":"Baer","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2021.106736_bib0065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2005-10-4073","article-title":"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial","volume":"108","author":"Brune","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2021.106736_bib0070","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood-2010-09-305649","article-title":"The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy","volume":"117","author":"Ghosh","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2021.106736_bib0075","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/cncr.28516","article-title":"Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808","volume":"120","author":"Kolitz","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2021.106736_bib0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2016.252","article-title":"Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)","volume":"31","author":"Blum","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.leukres.2021.106736_bib0085","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/leu.2012.153","article-title":"A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission","volume":"26","author":"Boumber","year":"2012","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2021.106736_bib0090","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00277-014-2047-7","article-title":"Survival improvement of poor-prognosis AML\/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents","volume":"93","author":"Ferrero","year":"2014","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2021.106736_bib0095","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/ajh.24087","article-title":"A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy","volume":"90","author":"Griffin","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2021.106736_bib0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2141.2010.08235.x","article-title":"Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy","volume":"150","author":"Grovdal","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"26","key":"10.1016\/j.leukres.2021.106736_bib0105","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2021.106736_bib0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood-2011-08-370825","article-title":"Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia","volume":"119","author":"Karp","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2021.106736_bib0115","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/1078-0432.CCR-10-1878","article-title":"A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias","volume":"17","author":"Lancet","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2021.106736_bib0120","first-page":"2963","article-title":"Preliminary results from an open-label, phase 2 study of tipifarnib in Chronic Myelomonocytic Leukemia (CMML)","volume":"130","author":"Patnaik","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2021.106736_bib0125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.leukres.2013.12.001","article-title":"Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432","volume":"38","author":"Erba","year":"2014","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.leukres.2021.106736_bib0130","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2141.2012.09165.x","article-title":"The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML","volume":"158","author":"Burnett","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2021.106736_bib0135","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2009-01-198093","article-title":"A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621017379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621017379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:55Z","timestamp":1758935035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621017379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":27,"alternative-id":["S0145212621017379"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106736","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106736"}}